Friday, August 12, 2022 8:01:42 AM
WALL, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer identity and access management (IAM) and large-scale identity solutions, featuring Identity-Bound Biometrics (IBB), today reported results for its second quarter ended June 30, 2022 (Q2’22). BIO-key is hosting a conference call today at 10:00 a.m. ET (details below) to review its results and outlook.
Highlights:
Q2’22 revenues rose 96% to $1.9M from $1.0M in Q2’21, driven by a $0.5M increase in software license fees, as well as $0.3M and $0.15M increases in hardware and services revenue, respectively.
Expanded PortalGuard Penetration with new customers, including YYK Enterprises Operations and a Texas City and New Channel Alliance Program partners, including the Amazon Web Services Partner Network, 3Eye Technologies and Darksteel Technologies.
BIO-key’s PortalGuard® platform was a gold recipient of Security Today magazine’s 2022 Govies Government Security Award in User Authentication/Identification/Credentialing and Management; the Publisher's Choice for Multi-factor Authentication (MFA) Award from Cyber Defense Magazine during RSA 2022; the 2022 Fortress Cyber Security Award in Authentication and Identity; and RemoteTech Breakthrough’s Identity Management Solution of the Year 2022.
BIO-key CEO Michael DePasquale commented, “Our second quarter and first half revenue demonstrate growing momentum in our base of annual recurring revenue (ARR) from software licenses, which is a core focus and principal value driver for our business. Our Q2’22 performance included the first full quarter of operating results from our Swivel Secure Europe operations acquired in March and the integration of this business is proceeding according to plan.
“PortalGuard continues to gain momentum in higher education, municipal governments, and enterprises as a high-value, easy-to-deploy solution for hybrid access needs. Our progress is being supported by a growing base of Channel Alliance Partners (CAP) around the world, strong customer references, an expanding base of industry awards, and our digital and direct sales and marketing initiatives. Customers are increasingly recognizing PortalGuard’s value, flexibility and support for sixteen multi-factor authentication factors, including BIO-key’s industry leading Identity Bound Biometric capabilities.
Outlook
“BIO-key has built a strong base of products and services and a growing global footprint of partnerships and direct sales resources to address the substantial cybersecurity and IAM needs around the world. Given our progress to date and the growing scope of opportunities we are identifying, we remain confident in achieving our full-year 2022 revenue guidance of $10-13M, representing growth of over 100% above 2021. We believe BIO-key is positioned to achieve break-even operations within this range, subject to our mix of hardware and higher-margin software revenue.
“Our guidance anticipates continued growth in recurring software license revenue to roughly 70% of the lower end of our revenue range, supported by hardware and services revenue contributions that are generally tied to specific projects. Our outlook is supported by our strong capital position, talented management and product development teams, and our expanding global sales, marketing and channel partner footprint.”
Financial Results
Q2’22 revenues increased 96% to $1.9M from $0.9M in Q2’21, driven by a 75.5% increase in software license revenue as well as solid growth in both hardware and services revenue.
Gross profit grew to $1.2M in Q2’22 from $0.8M in Q2’21, due primarily to increased revenues. Gross profit margin declined from 75% in Q2’21 to 63% in Q2’22, due to growth in lower-margin hardware revenue and a decline in the gross margin realized on license fees as a result of third party-software required for Swivel Secure licenses.
Total operating expenses increased to $2.8M in Q2’22 from $1.9M in Q2’21, reflecting a $0.6M increase in selling, general and administrative expenses and a $0.3M increase in research, development and engineering expenses. Increases included the consolidation of Swivel Secure and increased personnel costs related to multiple new hires. Higher research, development & engineering costs were attributable to costs associated with the development and Q2 launch of significant enhancements and updates to our MobileAuth application, the only multi-factor authentication mobile app that integrates Identity-Bound Biometrics with other authentication modalities.
BIO-key reported a net loss of $1.7M, or $0.21 per share, compared to a Q2’21 loss of $1.2M, or $0.15 per share. Weighted average basic shares outstanding were approximately 8.1M in Q2’22 and 7.8M in Q2’21.
Financial Strength
BIO-key ended the second quarter with working capital of $8.8M, including $4.9M of cash and cash equivalents and $4.9M in inventory, and a book value of $13.6M, or approximately $1.61 per share.
Conference Call Details
Date / Time: Friday, August 12th at 10 a.m. ET
Call Dial In #: 1-877-418-5460 U.S. or 1-412-717-9594 International
Live Webcast / Replay: Investor Webcast & Replay – Available for 3 months.
Audio Replay: 1-877-344-7529 U.S. or 1-412-317-0088 Int’l; code 6599160
About BIO-key International, Inc. (www.BIO-key.com)
BIO-key has over two decades of expertise in providing authentication technology for thousands of organizations and millions of users and is revolutionizing authentication with biometric-centric, multi-factor identity and access management (IAM) solutions, including PortalGuard that provides convenient and secure access to devices, information, applications, and high-value transactions. BIO-key's patented software and hardware solutions, with industry-leading biometric capabilities, enable large-scale on-premises and Identity-as-a-Service (IDaaS) solutions as well as customized enterprise and cloud solutions.
BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology and identity access management industries; market acceptance of biometric products generally and our products under development; our ability to execute and deliver on contracts in Africa; our ability to expand into Asia, Africa and other foreign markets; our ability to integrate the operations and personnel of PistolStar and Swivel Secure into our business; fluctuations in foreign currency exchange rates; the duration and severity of the current coronavirus COVID-19 pandemic and its effect on our business operations, sales cycles, personnel, and the geographic markets in which we operate; the duration and extent of continued hostilities in Ukraine and its impact on our European customers, delays in the development of products and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021 and other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise.
Engage with BIO-key
Facebook – Corporate: https://www.facebook.com/BIOkeyInternational/
LinkedIn – Corporate: https://www.linkedin.com/company/bio-key-international
Twitter – Corporate: @BIOkeyIntl
Twitter – Investors: @BIO_keyIR
StockTwits: BIO_keyIR
Media Contact Investor Contact
Erin Knapp William Jones, David Collins
Matter Communications Catalyst IR
BIO-key@matternow.com BKYI@catalyst-ir.com
914-260-3158 212-924-9800
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
June 30,
2022 December 31,
2021
(Unaudited)
ASSETS
Cash and cash equivalents $ 4,893,042 $ 7,754,046
Accounts receivable, net 2,039,062 970,626
Due from factor 76,940 49,500
Note receivable, net of allowance 119,644 82,000
Inventory 4,888,601 4,940,660
Prepaid expenses and other 331,697 216,041
Total current assets 12,348,986 14,012,873
Resalable software license rights 43,768 48,752
Investment – debt security, net 302,821 452,821
Equipment and leasehold improvements, net 135,237 69,168
Capitalized contract costs, net 301,225 249,012
Deposits and other assets 8,712 8,712
Note receivable, net of allowance 68,356 113,000
Operating lease right-of-use assets 206,792 254,100
Intangible assets, net 1,952,606 1,298,077
Goodwill 2,256,402 1,262,526
Total non-current assets 5,275,919 3,756,168
TOTAL ASSETS $ 17,624,905 $ 17,769,041
LIABILITIES
Accounts payable $ 1,279,301 $ 427,772
Accrued liabilities 849,719 828,997
Earnout payable – Swivel acquisition 500,000 -
Government loan – BBVA Bank, current portion 122,000 -
Deferred revenue, current portion 588,949 565,355
Operating lease liabilities, current portion 192,581 177,188
Total current liabilities 3,532,550 1,999,312
Deferred revenue, net of current portion 71,524 67,300
Operating lease liabilities, net of current portion 22,004 86,974
Government loan – BBVA Bank, net of current portion 379,287 -
Total non-current liabilities 472,815 154,274
TOTAL LIABILITIES 4,005,365 2,153,586
Commitments and Contingencies
STOCKHOLDERS’ EQUITY
Common stock — authorized, 170,000,000 shares; issued and outstanding; 8,441,574 and 7,853,759 of $.0001 par value at June 30, 2022 and December 31, 2021, respectively 844 786
Additional paid-in capital 121,022,606 120,190,139
Accumulated other comprehensive loss (110,081 ) -
Accumulated deficit (107,293,830 ) (104,575,470 )
TOTAL STOCKHOLDERS’ EQUITY 13,619,540 15,615,455
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 17,624,905 $ 17,769,041
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
Three months ended
June 30, Six months ended
June 30,
2022 2021 2022 2021
Revenues
Services $ 435,106 $ 286,641 $ 830,910 $ 666,663
License fees 1,162,148 662,193 2,622,331 1,141,151
Hardware 349,861 43,256 435,045 1,072,914
Total revenues 1,947,115 992,090 3,888,286 2,880,728
Costs and other expenses
Cost of services 180,677 158,440 391,590 334,384
Cost of license fees 358,136 48,373 431,366 87,342
Cost of hardware 185,140 32,756 238,438 584,478
Total costs and other expenses 723,953 239,569 1,061,394 1,006,204
Gross profit 1,223,162 752,521 2,826,892 1,874,524
Operating Expenses
Selling, general and administrative 2,006,573 1,374,084 3,804,571 2,890,482
Research, development and engineering 784,083 490,952 1,589,349 932,603
Total Operating Expenses 2,790,656 1,865,036 5,393,920 3,823,085
Operating loss (1,567,494 ) (1,112,515 ) (2,567,028 ) (1,948,561 )
Other income (expense)
Interest income 77 832 208 3,447
Loss on foreign currency transactions - (50,000 ) - (50,000 )
Investment-debt security reserve (150,000 ) - (150,000 ) -
Interest expense (1,540 ) - (1,540 ) (18,000 )
Total other income (expense), net (151,463 ) (49,168 ) (151,332 ) (64,553 )
Net loss $ (1,718,957 ) $ (1,161,683 ) $ (2,718,360 ) $ (2,013,114 )
Comprehensive loss:
Net loss $ (1,718,957 ) $ (1,161,683 ) $ (2,718,360 ) $ (2,013,114 )
Other comprehensive income – Foreign currency translation adjustment (165,883 ) - (110,081 ) -
Comprehensive loss $ (1,884,840 ) $ (1,161,683 ) $ (2,828,441 ) $ (2,013,114 )
Basic and Diluted Loss per Common Share $ (0.21 ) $ (0.15 ) $ (0.34 ) $ (0.26 )
Weighted Average Common Shares Outstanding:
Basic and diluted 8,098,020 7,776,190 7,992,102 7,774,946
Wick(w50)
Recent BKYI News
- BIO-key International, Inc. Receives Notice of Non-Compliance from Nasdaq • GlobeNewswire Inc. • 04/22/2024 08:30:00 PM
- Switzerland’s Canton of Ticino Implements BIO-key’s Multi-Factor Authentication Solution in its Information Systems Center • GlobeNewswire Inc. • 04/09/2024 01:15:00 PM
- Identity and Access Management Software Provider BIO-key Preliminary 2023 Results: Operating Loss Trimmed Approx. $3.5M on Approx. 29% Revenue Growth to $9.1M; Investor Call Tomorrow at 10am ET • GlobeNewswire Inc. • 04/01/2024 08:45:00 PM
- Identity and Access Management/Cybersecurity Solutions Provider BIO-key International Hosts Q4 Investor Call Tues., Apr. 2nd at 10am ET • GlobeNewswire Inc. • 03/27/2024 01:30:00 PM
- Humanity International Investments Hits Major Milestones in Digital Identity with the Humanity Protocol Initiative in Partnership with BIO-key International • GlobeNewswire Inc. • 03/12/2024 06:17:46 PM
- BIO-key Receives $1.5M Pre-Paid, Two-Year Software Subscription Order for its Biometric Identification Platform • GlobeNewswire Inc. • 02/20/2024 01:59:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/16/2024 10:02:13 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:30:35 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:04:15 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/13/2024 05:15:36 AM
- Bridgetown, Barbados Credit Union Selects BIO-key’s PortalGuard to Enhance Access to Shared Workstations Including Biometrics • GlobeNewswire Inc. • 02/06/2024 01:59:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/30/2024 10:31:29 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/25/2024 09:01:47 PM
- Tragsa Group Enhances Cybersecurity with BIO-key’s Multi-Factor Authentication Solution • GlobeNewswire Inc. • 01/22/2024 10:15:00 AM
- Haver & Boecker Implements Single Sign-On (SSO) with Multifactor Authentication via P&W Netzwerk and BIO-key Europe to Secure and Streamline User Access • GlobeNewswire Inc. • 01/17/2024 09:59:00 AM
- NJ-based Authentication Solutions Provider BIO-key to Review Growth Strategy and Progress at The Microcap Conf. in Atlantic City – Presentation Wed., Jan 31 at 10:50am ET • GlobeNewswire Inc. • 01/16/2024 01:59:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 04:54:32 PM
- Fargo, ND and Junction City, KS Choose BIO-key PortalGuard For Secure Access via Biometric Authentication • GlobeNewswire Inc. • 01/11/2024 12:58:00 PM
- BIO-key PortalGuard Wins 2024 Business Intelligence Group’s BIG Innovation Award for its Authentication Software • GlobeNewswire Inc. • 01/10/2024 02:01:00 PM
- Denmark’s Ministry of Foreign Affairs Bolsters Network Security via IT2Trust and BIO-key® • GlobeNewswire Inc. • 01/08/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 10:28:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 10:20:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 10:14:48 PM
- Portugal’s Judiciary Police Enhances Security Infrastructure via Securnet and BIO-key • GlobeNewswire Inc. • 01/02/2024 10:01:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM